search
Back to results

Chronic Pain Diagnosis and Treatment in Torture Survivors

Primary Purpose

Pain, Pain, Chronic

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pain Evaluation and BPISF
Surveys, a fingerstick blood sample, EMAs, and a digital wearable device
Sponsored by
Weill Medical College of Cornell University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Pain focused on measuring asylum, torture, refugee

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ≥ 18 years old
  • Survived torture as defined by the World Medical Association
  • Consented to being contacted by our research team

Exclusion Criteria:

  • Non-tortured refugees seeking asylum through T visas (trafficking), U visas (victims of violence in the US), Violence Against Women Act (VAMA), and Special Immigrant Juveniles (SIJ)
  • Pregnant women

Sites / Locations

  • Bellevue/New York University Program for Survivors of Torture
  • Mount Sinai Human Rights Program
  • Columbia University Human Rights Initiative and Asylum Clinic
  • Weill Cornell MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

No Intervention

Experimental

Arm Label

Aim 1: Pain Evaluation

Aim 2: Qualitative Interview

Aim 3: Enrollment in a digital program assessing stress, pain, and cardiovascular health

Arm Description

Participants will complete the validated pain questionnaire, the Brief Pain Inventory Short Form (BPISF). Participants will receive a non-invasive physical exam and pain assessment by a pain specialist.

Participants will complete individual interviews moderated by the research staff. Interviews will be based on the guide but will be minimally structured to facilitate exploration of novel topics as raised by participants and to ensure information-rich data on topics of interest. Individual interviews will be ~30-45 minutes in length, conducted in the subject's primary language with the use of an interpreter as appropriate. All interviews will be audio-recorded with participants' permission, transcribed, and translated into English for analysis.

Continuous cardiovascular, stress, and pain data collection will occur for 6 months after enrollment. Biometric data including continuous heart rate, actigraphy, sleep, and derived physiological parameters will be collected using the wearable device. Pain and stress evaluations will be administered via a smartphone app as a survey of stress, pain, or cardiovascular symptoms. Participants will complete surveys assessing chronic pain, mental health, trauma history, migration stress, and cardiovascular risk factors and disease Total cholesterol, HDL, LDL, triglycerides, and glucose will be measured using a lipid analyzer with a fingerstick blood sample. Height, weight, and blood pressure will also be measured.

Outcomes

Primary Outcome Measures

Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by the United Nations Istanbul Protocol (UNIP).
The UNIP results in a binary "yes" or "no" clinical pain diagnosis by the evaluator.
Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by the United Nations Istanbul Protocol (UNIP) and the Brief Pain Inventory Short Form (BPISF).
As the UNIP results in a binary "yes" or "no" clinical pain diagnosis by the evaluator, the continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences interference as mild, moderate, or severe pain will be categorized as "yes" for pain; any participant who experiences pain as mild, moderate, or severe will be categorized as "yes" for pain. A score of 0 will be categorized as "no" for pain on the BPISF.
Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by pain specialist evaluation.
The presence of pain detected by the pain specialist evaluation will be categorized as a binary "yes" or "no".
Aim 2: Themes emerging across qualitative interview transcripts.
A thematic coding scheme will be created following the main points of the interview guide. Reports will be generated for each code and narratives will be analyzed for common themes related to acceptability of pain treatments and the relationship between stress and chronic pain. We will utilize the data gained from this Aim to adapt the design of our proposed evidence-based somatic pain treatment model.
Aim 3: The recruitment as measured by the number of participants enrolled.
The investigators aim to recruit 20 participants.
Aim 3: The retention as measured by the number of participants who complete the follow-up appointment 6 months after their baseline appointment.
Aim 3: The adherence as measured by the number of participants who answer 1 or more Ecological Momentary Assessment (EMA) questions.
Participants are sent EMA questions each week to assess their levels of stress and pain, as well as their cardiovascular symptoms.
Aim 3: The adherence as measured by the number of participants who wear their Fitbit for 1 or more days.

Secondary Outcome Measures

Aim 3: Number of participants for whom "yes" is indicated for pain as assessed by the Brief Pain Inventory Short Form (BPISF).
The continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences mild, moderate, or severe pain or pain interference will be categorized as "yes" for pain; a score of 0 will be categorized as "no" for pain on the BPISF.
Aim 3: Number of participants for whom "yes" is indicated for pain as assessed by the Brief Pain Inventory Short Form (BPISF).
The continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences mild, moderate, or severe pain or pain interference will be categorized as "yes" for pain; a score of 0 will be categorized as "no" for pain on the BPISF.
Aim 3: The mean score for pain severity as assessed by the Brief Pain Inventory Short Form (BPISF).
Questions 3-6 on the BPISF assess mean pain severity score; these questions are scored on a scale of 0 to 10, with 0 indicating "no pain" and 10 indicating "pain as bad as you can imagine."
Aim 3: The mean score for pain severity as assessed by the Brief Pain Inventory Short Form (BPISF).
Questions 3-6 on the BPISF assess mean pain severity score; these questions are scored on a scale of 0 to 10, with 0 indicating "no pain" and 10 indicating "pain as bad as you can imagine."
Aim 3: The mean score for pain interference as assessed by the Brief Pain Inventory Short Form (BPISF).
Question 9 on the BPISF, comprised of 7 parts, assesses mean pain interference; these questions are scored on a scale of 0 to 10, with 0 indicating "does not interfere" and 10 indicating "completely interferes."
Aim 3: The mean score for pain interference as assessed by the Brief Pain Inventory Short Form (BPISF).
Question 9 on the BPISF, comprised of 7 parts, assesses mean pain interference; these questions are scored on a scale of 0 to 10, with 0 indicating "does not interfere" and 10 indicating "completely interferes."
Aim 3: Number of participants with positive scores on the Refugee Health Screener-15 (RHS-15).
Symptoms are scored from 0 to 4. A score of 0 indicates "not at all" and a score of 4 indicates "extremely." The survey also asks participants to rate their distress according to a distress thermometer; the thermometer scale ranges from 0 to 10, with 0 indicating "no distress" and 10 indicating "extreme distress." Screening is defined as positive with a total score greater than or equal to 12 on the first 14 items or a ranking greater than 5 on the distress thermometer.
Aim 3: Number of participants with positive scores on the Refugee Health Screener-15 (RHS-15).
Symptoms are scored from 0 to 4. A score of 0 indicates "not at all" and a score of 4 indicates "extremely." The survey also asks participants to rate their distress according to a distress thermometer; the thermometer scale ranges from 0 to 10, with 0 indicating "no distress" and 10 indicating "extreme distress." Screening is defined as positive with a total score greater than or equal to 12 on the first 14 items or a ranking greater than 5 on the distress thermometer.
Aim 3: Number of participants with positive scores on the Refugee Trauma History Checklist (RTHC).
The RTHC is comprised of binary "yes" and "no" questions. The RTHC is considered quantitatively positive if any item is marked as "yes."
Aim 3: Number of participants with positive scores on the Stress of Immigration - Short Form (SOIS-SF).
The SOIS-SF is considered positive if the participant answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress."
Aim 3: Number of participants with positive scores on the Stress of Immigration - Short Form (SOIS-SF).
The SOIS-SF is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress."
Aim 3: The mean score on the Stress of Immigration - Short Form (SOIS-SF).
The SOIS-SF subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress." The SOIS-SF is scored by averaging the scores of the 5-item survey. The mean of non-missing items results in a score of 1 to 5.
Aim 3: The mean score on the Stress of Immigration - Short Form (SOIS-SF).
The SOIS-SF subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress." The SOIS-SF is scored by averaging the scores of the 5-item survey. The mean of non-missing items results in a score of 1 to 5.
Aim 3: Number of participants who say they would be willing to provide a saliva or hair sample to measure cortisol levels in a hypothetical future study.
Aim 3: Number of participants with positive scores on the Refugee Post Migration Stress Scale (RPMS).
The RPMS is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with 1 indicating "never" and 5 indicating "very often." Items marked as a subscale score greater than 1 on the RPMS will be considered sources of stress.
Aim 3: Number of participants with positive scores on the Refugee Post Migration Stress Scale (RPMS).
The RPMS is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with 1 indicating "never" and 5 indicating "very often." Items marked as a subscale score greater than 1 on the RPMS will be considered sources of stress.
Aim 3: Number of participants with positive scores on the Atherosclerotic Cardiovascular Disease Pooled Cohort Equation (ASCVD PCE).
Positive scores are indicated by ≥7.5% 10-year ASCVD risk (defined as first-occurrence nonfatal and fatal myocardial infarction (MI) and nonfatal and fatal stroke).
Aim 3: Number of participants with positive scores on the Atherosclerotic Cardiovascular Disease Pooled Cohort Equation (ASCVD PCE).
Positive scores are indicated by ≥7.5% 10-year ASCVD risk (defined as first-occurrence nonfatal and fatal myocardial infarction (MI) and nonfatal and fatal stroke).
Aim 3: Number of participants with positive scores on the World Health Organization Rose Angina Questionnaire (WHOAQ).
The WHOAQ is used to determine if a participant has experienced symptoms of a heart attack. The WHOAQ is positive if any symptoms are recorded.
Aim 3: Number of participants with positive scores on the World Health Organization Rose Angina Questionnaire (WHOAQ).
The WHOAQ is used to determine if a participant has experienced symptoms of a heart attack. The WHOAQ is positive if any symptoms are recorded.
Aim 3: Number of participants with positive scores on the Questionnaire Verifying Stroke Free Status (QVSFS).
The QVSFS is used to determine if a participant has experienced symptoms of a stroke. The QVSFS is positive if any questions are answered in the affirmative.
Aim 3: Number of participants with positive scores on the Questionnaire Verifying Stroke Free Status (QVSFS).
The QVSFS is used to determine if a participant has experienced symptoms of a stroke. The QVSFS is positive if any questions are answered in the affirmative.
Aim 3: Number of participants who have self-reports of Cardiovascular disease (CVD) symptoms and events.
Participants will be asked if they have experienced any of the following symptoms: anxiety, chest pain, depression, dizziness, dyspnea, fatigue.
Aim 3: Number of participants who have self-reports of Cardiovascular disease (CVD) symptoms and events.
Participants will be asked if they have experienced any of the following symptoms: anxiety, chest pain, depression, dizziness, dyspnea, fatigue.
Aim 3: Number of participants who have pain, stress, or CVD symptoms, as signalled by continuous biometric data.
Biometric data including continuous heart rate, actigraphy, sleep, and derived physiological parameters (e.g., resting heart rate and estimated energy expenditure) will be collected using the wrist-worn wearable device.

Full Information

First Posted
November 11, 2020
Last Updated
September 5, 2023
Sponsor
Weill Medical College of Cornell University
Collaborators
National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT04629963
Brief Title
Chronic Pain Diagnosis and Treatment in Torture Survivors
Official Title
Chronic Pain Diagnosis and Treatment in Torture Survivors
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 14, 2021 (Actual)
Primary Completion Date
June 30, 2025 (Anticipated)
Study Completion Date
August 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weill Medical College of Cornell University
Collaborators
National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal Aim 1 of this investigation is to characterize the diagnosis of chronic pain in torture survivors. The investigators hypothesize that using a validated pain screen to supplement the existing United Nations Istanbul Protocol can improve the ability to detect pain from 15% to 90% in this study population. Investigators will test this hypothesis by conducting a prospective, blind comparison to gold standard study. The goal of Aim 2 is to evaluate the acceptability of somatic pain treatment using qualitative interviews of torture survivors. The goal of Aim 3 is to assess the feasibility of recruiting and retaining participants in a digital pain program over six months.
Detailed Description
The objective of this application is to improve the diagnosis and treatment of chronic pain in torture survivors. The central hypothesis, based on strong preliminary data from 25 subjects from the Weill Cornell Center for Human Rights, is that the novel application in torture survivors of a validated pain screen, the Brief Pain Inventory Short Form (BPISF), can supplement the United Nations Istanbul Protocol (UNIP) and improve its sensitivity for pain from 15% to 90%, as compared to the gold standard (a pain specialist). The rationale for the investigation is to improve the diagnosis of pain in torture survivors, leading to targeted treatment. The objectives of this study are to improve the diagnosis of pain in torture survivors with the novel utilization in this population of a pain screen. The findings of this study also have implications for other populations that experience complex trauma such as veterans, prisoners of war, and sexual violence survivors. The primary objective of the qualitative interview portion is to gain an understanding of how participants perceive, react to, and might utilize somatic pain treatment. We aim to qualitatively assess the challenges and acceptability of a proposed, evidence-based somatic pain treatment model, novel in its implementation in torture survivors: physical therapy and/or non-opioid analgesics and/or trigger point injections. We will use the Gelberg and Andersen Behavioral Model of Health Care Utilization for Vulnerable Populations as a conceptual framework to conduct qualitative interviews with 30 participants purposively sampled from Study Aim 1. Data with regard to acceptability and practicality from interviews will be used to adapt our proposed evidence-based somatic pain treatment for torture survivors. The primary objective of Aim 3 is to answer critical questions on the feasibility of a subsequent clinical trial to treat somatic pain in torture survivors. As a secondary objective, we will analyze the prevalence of migration stress, pain, and cardiovascular disease, and their relationship over time, in refugee torture survivors. The primary objective of this sub-study is the recruitment, retention, and adherence of participants to the digital program over a six-month period. The secondary objectives of this sub-study are the assessment of pain, mental health status, trauma history, migration stress, and cardiovascular risk factors and diseases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Pain, Chronic
Keywords
asylum, torture, refugee

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Investigators will enroll participants from human rights centers and compare the diagnostic ability of the United Nations Istanbul Protocol (UNIP) alone to the UNIP plus a validated pain screen (BPISF), both against the gold standard for pain assessment (pain specialist exam). Participants will complete individual interviews during which we will present our somatic pain treatment model and receive feedback on challenges, limitations, and acceptability of the interventions. A feasibility sub-study will be conducted with the primary outcome being recruitment and retention of participants over a 6-month period. Secondary outcomes include analysis of study visit data (i.e. migration stress, pain, cardiovascular) collected at enrollment and again after 6 months. Digital and biometric data will be collected continuously from a study-provided smartphone application and wearable fitness device for up to 6 months.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Aim 1: Pain Evaluation
Arm Type
Experimental
Arm Description
Participants will complete the validated pain questionnaire, the Brief Pain Inventory Short Form (BPISF). Participants will receive a non-invasive physical exam and pain assessment by a pain specialist.
Arm Title
Aim 2: Qualitative Interview
Arm Type
No Intervention
Arm Description
Participants will complete individual interviews moderated by the research staff. Interviews will be based on the guide but will be minimally structured to facilitate exploration of novel topics as raised by participants and to ensure information-rich data on topics of interest. Individual interviews will be ~30-45 minutes in length, conducted in the subject's primary language with the use of an interpreter as appropriate. All interviews will be audio-recorded with participants' permission, transcribed, and translated into English for analysis.
Arm Title
Aim 3: Enrollment in a digital program assessing stress, pain, and cardiovascular health
Arm Type
Experimental
Arm Description
Continuous cardiovascular, stress, and pain data collection will occur for 6 months after enrollment. Biometric data including continuous heart rate, actigraphy, sleep, and derived physiological parameters will be collected using the wearable device. Pain and stress evaluations will be administered via a smartphone app as a survey of stress, pain, or cardiovascular symptoms. Participants will complete surveys assessing chronic pain, mental health, trauma history, migration stress, and cardiovascular risk factors and disease Total cholesterol, HDL, LDL, triglycerides, and glucose will be measured using a lipid analyzer with a fingerstick blood sample. Height, weight, and blood pressure will also be measured.
Intervention Type
Other
Intervention Name(s)
Pain Evaluation and BPISF
Intervention Description
Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
Intervention Type
Other
Intervention Name(s)
Surveys, a fingerstick blood sample, EMAs, and a digital wearable device
Intervention Description
The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
Primary Outcome Measure Information:
Title
Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by the United Nations Istanbul Protocol (UNIP).
Description
The UNIP results in a binary "yes" or "no" clinical pain diagnosis by the evaluator.
Time Frame
Day 1 (One-time Research Appointment)
Title
Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by the United Nations Istanbul Protocol (UNIP) and the Brief Pain Inventory Short Form (BPISF).
Description
As the UNIP results in a binary "yes" or "no" clinical pain diagnosis by the evaluator, the continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences interference as mild, moderate, or severe pain will be categorized as "yes" for pain; any participant who experiences pain as mild, moderate, or severe will be categorized as "yes" for pain. A score of 0 will be categorized as "no" for pain on the BPISF.
Time Frame
Day 1 (One-time Research Appointment)
Title
Aim 1: Number of participants for whom "yes" is indicated for pain as assessed by pain specialist evaluation.
Description
The presence of pain detected by the pain specialist evaluation will be categorized as a binary "yes" or "no".
Time Frame
Day 1 (One-time Research Appointment)
Title
Aim 2: Themes emerging across qualitative interview transcripts.
Description
A thematic coding scheme will be created following the main points of the interview guide. Reports will be generated for each code and narratives will be analyzed for common themes related to acceptability of pain treatments and the relationship between stress and chronic pain. We will utilize the data gained from this Aim to adapt the design of our proposed evidence-based somatic pain treatment model.
Time Frame
Day 1 (One-time Research Appointment)
Title
Aim 3: The recruitment as measured by the number of participants enrolled.
Description
The investigators aim to recruit 20 participants.
Time Frame
1.5 years
Title
Aim 3: The retention as measured by the number of participants who complete the follow-up appointment 6 months after their baseline appointment.
Time Frame
6 months
Title
Aim 3: The adherence as measured by the number of participants who answer 1 or more Ecological Momentary Assessment (EMA) questions.
Description
Participants are sent EMA questions each week to assess their levels of stress and pain, as well as their cardiovascular symptoms.
Time Frame
6 months
Title
Aim 3: The adherence as measured by the number of participants who wear their Fitbit for 1 or more days.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Aim 3: Number of participants for whom "yes" is indicated for pain as assessed by the Brief Pain Inventory Short Form (BPISF).
Description
The continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences mild, moderate, or severe pain or pain interference will be categorized as "yes" for pain; a score of 0 will be categorized as "no" for pain on the BPISF.
Time Frame
Baseline appointment
Title
Aim 3: Number of participants for whom "yes" is indicated for pain as assessed by the Brief Pain Inventory Short Form (BPISF).
Description
The continuous BPISF will be converted into a binary "yes" or "no" for pain. Any participant who experiences mild, moderate, or severe pain or pain interference will be categorized as "yes" for pain; a score of 0 will be categorized as "no" for pain on the BPISF.
Time Frame
6-month follow-up appointment
Title
Aim 3: The mean score for pain severity as assessed by the Brief Pain Inventory Short Form (BPISF).
Description
Questions 3-6 on the BPISF assess mean pain severity score; these questions are scored on a scale of 0 to 10, with 0 indicating "no pain" and 10 indicating "pain as bad as you can imagine."
Time Frame
Baseline appointment
Title
Aim 3: The mean score for pain severity as assessed by the Brief Pain Inventory Short Form (BPISF).
Description
Questions 3-6 on the BPISF assess mean pain severity score; these questions are scored on a scale of 0 to 10, with 0 indicating "no pain" and 10 indicating "pain as bad as you can imagine."
Time Frame
6-month follow-up appointment
Title
Aim 3: The mean score for pain interference as assessed by the Brief Pain Inventory Short Form (BPISF).
Description
Question 9 on the BPISF, comprised of 7 parts, assesses mean pain interference; these questions are scored on a scale of 0 to 10, with 0 indicating "does not interfere" and 10 indicating "completely interferes."
Time Frame
Baseline appointment
Title
Aim 3: The mean score for pain interference as assessed by the Brief Pain Inventory Short Form (BPISF).
Description
Question 9 on the BPISF, comprised of 7 parts, assesses mean pain interference; these questions are scored on a scale of 0 to 10, with 0 indicating "does not interfere" and 10 indicating "completely interferes."
Time Frame
6-month follow-up appointment
Title
Aim 3: Number of participants with positive scores on the Refugee Health Screener-15 (RHS-15).
Description
Symptoms are scored from 0 to 4. A score of 0 indicates "not at all" and a score of 4 indicates "extremely." The survey also asks participants to rate their distress according to a distress thermometer; the thermometer scale ranges from 0 to 10, with 0 indicating "no distress" and 10 indicating "extreme distress." Screening is defined as positive with a total score greater than or equal to 12 on the first 14 items or a ranking greater than 5 on the distress thermometer.
Time Frame
Baseline appointment
Title
Aim 3: Number of participants with positive scores on the Refugee Health Screener-15 (RHS-15).
Description
Symptoms are scored from 0 to 4. A score of 0 indicates "not at all" and a score of 4 indicates "extremely." The survey also asks participants to rate their distress according to a distress thermometer; the thermometer scale ranges from 0 to 10, with 0 indicating "no distress" and 10 indicating "extreme distress." Screening is defined as positive with a total score greater than or equal to 12 on the first 14 items or a ranking greater than 5 on the distress thermometer.
Time Frame
6-month follow-up appointment
Title
Aim 3: Number of participants with positive scores on the Refugee Trauma History Checklist (RTHC).
Description
The RTHC is comprised of binary "yes" and "no" questions. The RTHC is considered quantitatively positive if any item is marked as "yes."
Time Frame
Baseline appointment
Title
Aim 3: Number of participants with positive scores on the Stress of Immigration - Short Form (SOIS-SF).
Description
The SOIS-SF is considered positive if the participant answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress."
Time Frame
Baseline appointment
Title
Aim 3: Number of participants with positive scores on the Stress of Immigration - Short Form (SOIS-SF).
Description
The SOIS-SF is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress."
Time Frame
6-month follow-up appointment
Title
Aim 3: The mean score on the Stress of Immigration - Short Form (SOIS-SF).
Description
The SOIS-SF subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress." The SOIS-SF is scored by averaging the scores of the 5-item survey. The mean of non-missing items results in a score of 1 to 5.
Time Frame
Baseline appointment
Title
Aim 3: The mean score on the Stress of Immigration - Short Form (SOIS-SF).
Description
The SOIS-SF subscale ranges from 1 to 5, with a score of 1 indicating "no stress" and a score of 5 indicating "severe stress." The SOIS-SF is scored by averaging the scores of the 5-item survey. The mean of non-missing items results in a score of 1 to 5.
Time Frame
6-month follow-up appointment
Title
Aim 3: Number of participants who say they would be willing to provide a saliva or hair sample to measure cortisol levels in a hypothetical future study.
Time Frame
Baseline appointment
Title
Aim 3: Number of participants with positive scores on the Refugee Post Migration Stress Scale (RPMS).
Description
The RPMS is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with 1 indicating "never" and 5 indicating "very often." Items marked as a subscale score greater than 1 on the RPMS will be considered sources of stress.
Time Frame
Baseline appointment
Title
Aim 3: Number of participants with positive scores on the Refugee Post Migration Stress Scale (RPMS).
Description
The RPMS is considered positive if the individual answered a subscale score of more than 1 for any of the individual items in the survey. The subscale ranges from 1 to 5, with 1 indicating "never" and 5 indicating "very often." Items marked as a subscale score greater than 1 on the RPMS will be considered sources of stress.
Time Frame
6-month appointment
Title
Aim 3: Number of participants with positive scores on the Atherosclerotic Cardiovascular Disease Pooled Cohort Equation (ASCVD PCE).
Description
Positive scores are indicated by ≥7.5% 10-year ASCVD risk (defined as first-occurrence nonfatal and fatal myocardial infarction (MI) and nonfatal and fatal stroke).
Time Frame
Baseline appointment
Title
Aim 3: Number of participants with positive scores on the Atherosclerotic Cardiovascular Disease Pooled Cohort Equation (ASCVD PCE).
Description
Positive scores are indicated by ≥7.5% 10-year ASCVD risk (defined as first-occurrence nonfatal and fatal myocardial infarction (MI) and nonfatal and fatal stroke).
Time Frame
6-month follow-up appointment
Title
Aim 3: Number of participants with positive scores on the World Health Organization Rose Angina Questionnaire (WHOAQ).
Description
The WHOAQ is used to determine if a participant has experienced symptoms of a heart attack. The WHOAQ is positive if any symptoms are recorded.
Time Frame
Baseline appointment
Title
Aim 3: Number of participants with positive scores on the World Health Organization Rose Angina Questionnaire (WHOAQ).
Description
The WHOAQ is used to determine if a participant has experienced symptoms of a heart attack. The WHOAQ is positive if any symptoms are recorded.
Time Frame
6-month follow-up appointment
Title
Aim 3: Number of participants with positive scores on the Questionnaire Verifying Stroke Free Status (QVSFS).
Description
The QVSFS is used to determine if a participant has experienced symptoms of a stroke. The QVSFS is positive if any questions are answered in the affirmative.
Time Frame
Baseline appointment
Title
Aim 3: Number of participants with positive scores on the Questionnaire Verifying Stroke Free Status (QVSFS).
Description
The QVSFS is used to determine if a participant has experienced symptoms of a stroke. The QVSFS is positive if any questions are answered in the affirmative.
Time Frame
6-month follow-up appointment
Title
Aim 3: Number of participants who have self-reports of Cardiovascular disease (CVD) symptoms and events.
Description
Participants will be asked if they have experienced any of the following symptoms: anxiety, chest pain, depression, dizziness, dyspnea, fatigue.
Time Frame
Baseline appointment
Title
Aim 3: Number of participants who have self-reports of Cardiovascular disease (CVD) symptoms and events.
Description
Participants will be asked if they have experienced any of the following symptoms: anxiety, chest pain, depression, dizziness, dyspnea, fatigue.
Time Frame
6-month follow-up appointment
Title
Aim 3: Number of participants who have pain, stress, or CVD symptoms, as signalled by continuous biometric data.
Description
Biometric data including continuous heart rate, actigraphy, sleep, and derived physiological parameters (e.g., resting heart rate and estimated energy expenditure) will be collected using the wrist-worn wearable device.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
(Aim 1) Inclusion Criteria: ≥ 18 years old Survived torture as defined by the World Medical Association Consented to being contacted by our research team Exclusion Criteria: Non-tortured refugees seeking asylum through T visas (trafficking), U visas (victims of violence in the US), Violence Against Women Act (VAMA), and Special Immigrant Juveniles (SIJ) Pregnant women (Aim 2) Inclusion Criteria: ≥ 18 years old Survived torture as defined by the World Medical Association Chronic pain as per Aim 1 findings Exclusion Criteria: Non-tortured refugees seeking asylum through T visas (trafficking), U visas (victims of violence in the US), Violence Against Women Act (VAMA), and Special Immigrant Juveniles (SIJ) Pregnant women (Aim 3): Inclusion Criteria ≥ 18 years old Survived torture as defined by the World Medical Association Chronic pain as per Aim 1 findings Personal smartphone Exclusion Criteria Non-tortured refugees seeking asylum through T visas (trafficking), U visas (victims of violence in the US), Violence Against Women Act (VAMA), and Special Immigrant Juveniles (SIJ) Pregnant women Planned move within 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gunisha Kaur, MA, MD
Phone
(212) 746-2461
Email
gus2004@med.cornell.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Michele Steinkamp, RN
Phone
2127462953
Email
mls9004@med.cornell.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gunisha Kaur, MA, MD
Organizational Affiliation
Weill Medical College of Cornell University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Claudia Hatef, BS
Organizational Affiliation
Weill Medical College of Cornell University
Official's Role
Study Director
Facility Information:
Facility Name
Bellevue/New York University Program for Survivors of Torture
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Moore, MD
Phone
212-263-7300
Email
sarah.moore@nyulangone.org
First Name & Middle Initial & Last Name & Degree
Sarah Moore, MD
Facility Name
Mount Sinai Human Rights Program
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth Singer, MD
Phone
212-523-3981
Email
elizabeth.singer@mssm.edu
First Name & Middle Initial & Last Name & Degree
Elizabeth Singer, MD
Facility Name
Columbia University Human Rights Initiative and Asylum Clinic
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Devlin, MD
Phone
212-305-6001
Email
mjd5@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Michael Devlin, MD
Facility Name
Weill Cornell Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gunisha Kaur, BA, MD
Phone
212-746-2461
Email
gus2004@med.cornell.edu
First Name & Middle Initial & Last Name & Degree
Michele Steinkamp, RN
Phone
2127462953
Email
mls9004@med.cornell.edu
First Name & Middle Initial & Last Name & Degree
Gunisha Kaur, MA, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Chronic Pain Diagnosis and Treatment in Torture Survivors

We'll reach out to this number within 24 hrs